LXRX Financial Facts
Loss from operations: -25.56MConsolidated net loss per common share, basic and diluted: -0.05
See Full Income Statement
Goodwill: 44.54M
Other assets: 88K
See Full Balance Sheet
Earnings History for Lexicon Pharmaceuticals, Inc. (LXRX)
|
Expand Research on LXRX
| Next EPS Date | 5/17/13 *Est. | EPS Growth Rate | +50.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -2.1% | Revenue Growth Rate | -36.4% *Last Qtr. |
| Average % Move 1-Wk after EPS | -0.5% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/21/13 | Q412 | -$0.05 | -$0.05 | $0.00 | $218K | $370K | N/A / N/A | N/A | +10.5% | Details | |
| 11/6/12 | Q312 | -$0.06 | -$0.06 | $0.00 | $372K | $600K | N/A / N/A | N/A | +12.8% | Details | |
| 7/31/12 | Q212 | -$0.05 | -$0.06 | +$0.01 | $555K | $350K | N/A / N/A | N/A | -7.1% | Details | |
2/22/12  |
 |
Q411 | -$0.10 | -$0.08 | -$0.02 | $343K | $290K | N/A / N/A | N/A | +39.9% | Details |
| 11/1/11 |
|
Q311 | -$0.08 | -$0.09 | +$0.01 | $355K | $320K | N/A / N/A | N/A | +82.6% | Details |
| 8/8/11 | Q211 | -$0.08 | -$0.09 | +$0.01 | $555K | $340K | N/A / N/A | N/A | +57.9% | Details | |
| 5/3/11 |
|
Q111 | -$0.09 | -$0.07 | -$0.02 | $596K | $1.06M | N/A / N/A | N/A | +31.5% | Details |
| 2/24/11 |
|
Q410 | -$0.13 | -$0.08 | -$0.05 | $1.3M | $1.13M | N/A / N/A | N/A | +22.8% | Details |
